Equities

Hansa Biopharma AB

Hansa Biopharma AB

Actions
  • Price (SEK)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7321,496889
Total Receivables, Net926532
Total Inventory1.510.970.24
Prepaid expenses304321
Other current assets, total------
Total current assets8551,605942
Property, plant & equipment, net273642
Goodwill, net------
Intangibles, net1364729
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets1,0181,6871,013
LIABILITIES
Accounts payable876253
Accrued expenses13412786
Notes payable/short-term debt000
Current portion long-term debt/capital leases7.507.176.89
Other current liabilities, total926825
Total current liabilities321265171
Total long term debt85978428
Total debt86779135
Deferred income tax0.370.410.43
Minority interest------
Other liabilities, total5.303555
Total liabilities1,1861,084255
SHAREHOLDERS EQUITY
Common stock555546
Additional paid-in capital3,0833,0222,573
Retained earnings (accumulated deficit)(3303)(2471)(1860)
Treasury stock - common(2.36)(2.59)(1.86)
Unrealized gain (loss)------
Other equity, total--0.000.00
Total equity(168)603758
Total liabilities & shareholders' equity1,0181,6871,013
Total common shares outstanding535244
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.